Protalix BioTherapeutics, Inc. Common Stock (PLX) Stock
AMEX · PLX
2.69
Fundamentals
Market cap
$216.74M
Price / Earnings ratio
11.5x
Price / Sales ratio
2.7x
Price / Book ratio
3.0x
Return on assets
0.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Protalix BioTherapeutics, Inc. Common Stock
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
SectorHealthcare
IndustryBiotechnology
Employees226
CEOMr. Dror Bashan
IPO DateMay 15, 1998
HeadquartersHackensack, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Dror Bashan | President, CEO & Director | 1967 |
| Mr. Gilad Mamlok | Senior VP, CFO Treasurer & Secretary | 1968 |
| Mr. Yaron Naos B.Sc., MBA | SVP & COO | 1964 |
| Ms. Yael Fellous | Vice President of Human Resources | — |
Fundamentals
Valuation
Market cap$216.74M
Price-to-sales ratio2.70
Price-to-book value3.05
Price-earnings ratio11.50
Return on Equity28.00%
Return on Sales0.27%
Return on Assets0.18%
PEG ratio-0.10
Earnings Per Share
Earnings Per Share$0.24
Income Statement
Average volume689,886
EBITDA$22.33M
1 year high (52w)$3.19
1 year low (52w)$1.60
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



